Fecal calgranulin C in patients with inflammatory bowel disease
Karin Malíčková Orcid.org 1,2, Martin Bortlík Orcid.org 1,3,4, Dana Ďuricová Orcid.org 1, Martin Lukáš Orcid.org 1, Luděk Hrdlička Orcid.org 5,6, Naděžda Machková Orcid.org 1, Milan Lukáš Orcid.org 1
+ Affiliation
Summary
The aims of the study are the analysis of fecal calgranulin C levels in patients with bowel inflammation; comparison with the fecal calprotectin test; calculation of sensitivity and specificity for the diagnosis of inflammatory bowel disease (IBD); determination of the variability parameters of enzyme-linked immunosorbent assay (ELISA) for calgranulin C detection.
Materials and Methods: Fifty fecal samples from patients with Crohn's disease (n = 21), ulcerative colitis (n = 19) and unspecified bowel disorders (n = 10) were analysed. The fecal levels of calprotectin (MRP8/14)and calgranulin C(MRP6) were compared intheeluates. Statistical data analysis consisted of a quantitative and qualitative results comparison, a measurement of variability parameters and diagnostic performance of both tests. In calgranulin Cthe reference range of normal values was estimated.
Results: A significant positive correlation between fecal calprotectin concentrations and calgranulin C was found (r = 0.829, p <0.001). During the qualitative analysis of the results, a method consensus was achieved in 90% of cases. Diagnostic sensitivity of fecal calgranulin C for diagnosis of IBD was 75%, and specificity reached 88%. Parameters of variability for fecal calgranulin C ELISA were in accordance with IS015189 requirements.
Conclusion: Calgranulin C is a new biomarker of intestinal inflammation. It shows significant correlation with fecal calprotectin but its level should be increased primarily in the course of a neutrophil-mediated inflammation.
Keywords
inflammatory bowel disease, calprotectinTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users